SpliceBio

Executive Summary

SpliceBio, founded in 2020 and headquartered in Barcelona, Spain, is a private biotechnology company pioneering protein splicing technology for therapeutic applications. Based on the foundational research of Dr. Vila-Perelló at Princeton University, the company's platform leverages engineered inteins to precisely splice proteins, enabling novel gene therapies and protein engineering solutions. Currently in Phase 2 development, SpliceBio is advancing its lead candidate targeting genetic disorders, with a focus on diseases where precise protein modulation is critical. The company's innovative approach has the potential to address previously undruggable targets, positioning it as a key player in the RNA and gene therapy landscape. With a strong scientific foundation and a growing pipeline, SpliceBio aims to transform the treatment paradigm for rare genetic diseases.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for lead candidate65% success
• H1 2027Strategic partnership or licensing deal for platform technology50% success
• Q3 2026Series B or C financing round to support pipeline expansion70% success